Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00004217 · ClinicalTrials.gov registry record · Phase 2
S9918 PSC 833, Daunorubicin, and Cytarabine in Treating Older Patients With Newly Diagnosed Acute Myeloid Leukemia
A Phase 2 study, sponsored by SWOG Cancer Research Network.
- Completed
- Registry status
- Phase 2
- Development phase
- 55
- Enrollment target
NCT00004217 is a Phase 2 study that has completed, run by SWOG Cancer Research Network. The registered enrollment target is 55 participants.
The verdict
NCT00004217, a Phase 2 study, has completed, sponsored by SWOG Cancer Research Network.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 55 participants
- Enrollment target
Study Summary
RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. PSC 833 may help chemotherapy drugs kill more cancer cells by making them more sensitive to the drugs. PURPOSE: Phase II trial to study the effectiveness of PSC 833, daunorubicin, and cytarabine in treating older patients who have newly diagnosed acute myeloid leukemia.
Interventions
- BIOLOGICAL filgrastim
- DRUG cytarabine
- BIOLOGICAL sargramostim
- DRUG daunorubicin hydrochloride
- DRUG valspodar
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 55 participants |
| Start Date | 2000-02 |
| Est. Completion | 2006-03 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00004217
The ClinicalTrials.gov registry entry for NCT00004217 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 55 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is SWOG Cancer Research Network, which has 270 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which filgrastim is the first listed.
NCT00004217 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00004217 about?
NCT00004217 is a clinical study titled "S9918 PSC 833, Daunorubicin, and Cytarabine in Treating Older Patients With Newly Diagnosed Acute Myeloid Leukemia". RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. PSC 833 may help chemotherapy drugs kill more cancer cells by making them more sensitive to the drugs. PURPOSE: Phase II trial to study the effectiveness of PSC 833, daunorubicin...
What is the current status of trial NCT00004217?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 55 participants. The study started on 2000-02. Estimated completion is 2006-03.
What interventions are being tested in trial NCT00004217?
The interventions under investigation include: filgrastim (BIOLOGICAL), cytarabine (DRUG), sargramostim (BIOLOGICAL), daunorubicin hydrochloride (DRUG), valspodar (DRUG).
Who is sponsoring clinical trial NCT00004217?
This trial is sponsored by SWOG Cancer Research Network, which has 270 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.